A small retrospective study with only 19 patients showed that mutp53 was predictive of response to pazopanib in patients with advanced STS.33 We speculate that certain TP53 pathogenic variants may present a vulnerability in STS for treatment targeting, similar to some of the well-characterized genomic lesions that have been targeted [37–41]. This evidence concerns the gene TP53 and telomere syndrome.